Sponsored by: Investment Center

Something new in your business?  Click here to submit your business press release

Chamber Corner | Main Street News | Job Hunt | Classifieds | Calendar | Illinois Lottery 

Exclusive: Biomet picks BAML, Goldman, JPMorgan to lead IPO - sources

Send a link to a friend  Share

[February 27, 2014]  By Olivia Oran and Soyoung Kim

NEW YORK (Reuters) - Biomet Inc, the U.S. medical device maker that was taken private by a private equity consortium for $11.4 billion in 2007, has hired underwriters for an initial public offering later this year, people familiar with the matter said on Wednesday.

The offering could come in the first half of 2014 and raise more than $1 billion, the people said, asking not to be identified because the matter is not public.

Biomet's owners -- Blackstone Group LP <BX.N>, Goldman Sachs Group Inc's <GS.N> private equity arm, KKR & Co LP <KKR.N> and TPG Capital LP -- have selected Bank of America Merrill Lynch <BAC.N>, Goldman Sachs Group <GS.N> and JPMorgan Chase & Co <JPM.N> to lead the IPO, the people said.

Blackstone and Biomet did not immediately respond to requests for comment. Representatives for TPG, KKR and the banks declined to comment.

Founded in 1977, and based in Warsaw, Indiana, Biomet designs, manufacturers and markets products that include dental implants and artificial hips joints. Biomet competes with Smith & Nephew PLC and Stryker Corp <SYK.N>.

Biomet's buyout was done at the top of the market. But since then the medical device industry was hit during the financial crisis as patients delayed surgery and joint replacements. Pricing pressure for hip and knee replacements has also impacted the sector.

Biomet is one of the few remaining large companies taken over by private equity firms during the buyout boom that has not yet gone public.

Other large private equity-owned companies that have gone public in the past 12 months include hotel chain Hilton Worldwide Holdings Inc <HLT.N>, oil and gas company Antero Resources Corp <AR.N> and industrials supply company HD Supply Holdings Inc <HDS.O>.

Biomet's sales topped $3 billion in the fiscal year ended May 31, 2013, up 8 percent from the previous year. Adjusted net income was $368 million, up 46 percent over the same period.

(Reporting by Olivia Oran and Soyoung Kim in New York; Additional reporting by Greg Roumeliotis in Berlin; Editing by Leslie Adler)

[ 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

< Top Stories index

Back to top